CC

Chintan Chandubhai Trentiya

Active Director Director DIN 11092760
DIN 11092760 First appointment May 2025 Primary industry Machinery and Equipment
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Chintan Chandubhai Trentiya

Data last updated:

Chintan Chandubhai Trentiya is a Director at Kts Pharmatech Private Limited (since 2025). The company operates in Machinery and Equipment.

DIN 11092760
Primary Designation Director
Industry Machinery and Equipment
First Appointment 06 May 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kts Pharmatech Private Limited U21009GJ2025PTC162558
Director06 May 20252025Active

Board colleagues of Chintan Chandubhai Trentiya

Directorship timeline

Open interactive timeline →
Kts Pharmatech Private Limited
Premium access

Shareholding and investment profile for Chintan Chandubhai Trentiya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chintan Chandubhai Trentiya

Chintan Chandubhai Trentiya currently holds 1 directorship: Kts Pharmatech Private Limited (Director, since 06 May 2025).

Chintan Chandubhai Trentiya was first appointed on 06 May 2025 as Director at Kts Pharmatech Private Limited.

The current boards of Chintan Chandubhai Trentiya's companies include Jimitkumar Vasudevbhai Patel (Kts Pharmatech Private Limited), Satishkumar Jayntilal Patel (Kts Pharmatech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available